Bernstein, MD

Chief of Division - Hepatology of Medicine,
Long Island Jewish Medical Center

Chief of Division - Hepatology of Medicine,
North Shore University Hospital

About the researcher:



Research Interests:

  • Viral Hepatitis B and C: Treatment and access to care
  • Fatty liver disease
  • Transient elastography

Research focus:

Research training opportunities for residents and fellows

  • Transient elastography in hepatitis B
  • Transient elastography in dialysis patients awaiting transplantation
  • Fatty liver disease and diabetes


University of Miami Affiliated Hospitals

Degree: Hepatology Fellowship

University of Miami Affiliated Hospitals

Degree: Gastroenterology Fellowship

Montefiore Medical School

Degree: Medical Residency

Montefiore Medical Center

Degree: Medical Internship

SUNY-Stony Brook School of Medicine

Degree: Medical School

Honors and awards

April 2015 - December 2019

GlaxoSmithKline IIS


  • Ferenci P, Bernstein DE, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Tsao N, Nyberg A, Box T, Younes Z, Green S, Baruch Y, Bhardari B, Catuntu F, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervath J, Pianas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-Ombitasvir and dasabuvir with or without ribavirin for HCV. NEJM 2014; 370; 1983-1992
  • Kowdley K, Gordon S, Reddy K, Rossaro L, Bernstein D, Lawitz E, Shiffman M, Schiff E,  Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie A, Pockros P, Subramanian M, Svarovskaia E, Hyland R, Pang P, Symonds W, McHutchison J, Muir A, Pound D, Fried M. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. NEJM 2014; 370:1879-1888
  • Kowdley KV, Lawitz E, Crespo I, Hassanein T, David M, DeMIcco M, Bernstein D, Afdhal N, Vierling JM, Gordon SC, Andeson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated inteferon alfa 2a and ribavirin for treatment naive patients with hepatitis C genotype 1 infection: an open l;abel, randomised multicenter phase 2 trial. Lancet 2013; 15: 2100-2107
  • Lawitz E, Lalezari JP, Hassasein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with peginterferon alfa 2a and ribavirin for non-cirrhotic, treatment naive patients with genotypes 1,2 and 3 hepatitis C infection: a randomised, double blind , phase 2 trial. Lancet Infectious Disease 2013; 13:401-408. 
  • Satapathy SK, Kim YJ, Kataria A, Shifteh A, Bhansali R, Cerulli M, Bernstein D. Higher prevalence and more severe coronary artery disease in hepatitis C virus infected patients: A case control study. Journal of Clinical and Experimental Hepatology 2013;:1-6